Thus, compounds that can restrain RTP801 expression or modulate the mTOR/Akt pathway may become therapeutic and delay neurodegeneration and neuronal cell death in PD (reviewed in Tarazi et al., 2014). The gene discussed is AKT1; the disease is Parkinson disease.